ストックスクリーナーアプリを入手
5.68
1.61%
0.09
アフターアワーズ：
5.69
0.01
+0.18%
前日終値:
$5.59
開ける：
$5.5
24時間の取引高:
30,820
Relative Volume:
0.60
時価総額：
$25.62M
収益：
$86.55M
当期純損益:
$-56.70M
株価収益率:
-2.209
EPS:
-2.5713
ネットキャッシュフロー:
$4.87M
1週間 パフォーマンス:
+13.37%
1か月 パフォーマンス:
-17.20%
6か月 パフォーマンス:
-24.21%
1年 パフォーマンス:
+68.95%
1日の値動き範囲:
$5.26
$5.8332
1週間の範囲:
$5.10
$5.8818
52週間の値動き範囲:
$2.813
$9.458
Harvard Bioscience Inc Stock (HBIO) Company Profile
名前
Harvard Bioscience Inc
セクター
電話
(508) 893-8999
住所
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, ALC, MDLN, RMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
5.68 | 25.21M | 86.55M | -56.70M | 4.87M | -2.5713 |
ISRG
Intuitive Surgical Inc
|
436.64 | 155.16B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.75 | 40.68B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.70 | 33.06B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.16 | 31.30B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
207.98 | 30.18B | 5.54B | 1.52B | 1.74B | 10.37 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-09 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-03-10 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2021-01-07 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-09 | 開始されました | Northland Capital | Outperform |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2019-07-08 | ダウングレード | Janney | Buy → Neutral |
| 2018-01-24 | 繰り返されました | Janney | Buy |
| 2018-01-23 | 繰り返されました | The Benchmark Company | Buy |
| 2016-11-17 | 開始されました | Singular Research | Buy |
| 2015-07-28 | 開始されました | The Benchmark Company | Buy |
すべてを表示
Harvard Bioscience Inc (HBIO) 最新ニュース
Harvard Bioscience: HBIO stock stalls, margin pressure in focus - Bez Kabli
HBIO PE Ratio & Valuation, Is HBIO Overvalued - Intellectia AI
Harvard Bioscience Slips as Traders Assess Support Levels; HBIO Down Nearly 3%Open Trading Community - Newser
Harvard Bioscience (HBIO) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.33Real Trader Insights - Newser
Harvard Bioscience stock (US4169061052): Q2 2025 mixed results still define the story - AD HOC NEWS
HBIO Stock Price, Quote & Chart | HARVARD BIOSCIENCE INC (NASDAQ:HBIO) - ChartMill
Harvard Bioscience, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HBIO) 2026-05-15 - Seeking Alpha
Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts - Investing.com UK
Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts By Investing.com - Investing.com Australia
Harvard Bioscience (HBIO) insider entity reports 293,676 shares, 6.5% stake - Stock Titan
Harvard Bioscience Transitions to Translational Science Focus in 2026 - HarianBasis.co
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2026 Earnings Call Transcript - Insider Monkey
Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New Product Innovations - GuruFocus
Harvard Bioscience Q1 2026 slides: margins rise amid revenue miss By Investing.com - Investing.com Nigeria
Harvard Bioscience Q1 2026 Earnings Call Transcript - MarketBeat
HBIO Maintains Positive Outlook for FY26 Financial Performance - GuruFocus
Harvard Bioscience (HBIO) Reports Q1 Earnings and Reaffirms 2026 Revenue Guidance - GuruFocus
Discontinued operations of Harvard Bioscience, Inc. – FWB:HBI0 - TradingView
Harvard Bioscience Reaffirms Full-Year 2026 Financial Guidance >HBIO - Moomoo
Harvard Bioscience: Consolidation of Manufacturing Operations Progressing on Schedule >HBIO - Moomoo
Harvard Bioscience (NASDAQ: HBIO) posts Q1 2026 loss as debt costs rise - Stock Titan
Harvard Bioscience, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
HBIO Forecasts Q2 Margins and Revenue Growth - GuruFocus
HBIO Sees Q1 Revenue at $20.8M, Positive Trends in Product Adoption - GuruFocus
Earnings call transcript: Harvard Bioscience Q1 2026 misses EPS forecast, stock drops - Investing.com UK
Harvard Bioscience reaffirms 2026 outlook for 2%-4% revenue growth as Project Viking targets $4M annual savings - MSN
Harvard Bioscience Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Harvard Bioscience (HBIO) Q1: EPS Not Disclosed, Revenue $20.8M - GuruFocus
Harvard Bioscience Q1 2026 slides: margins rise amid revenue miss - Investing.com
Harvard Bioscience Still Sees 2026 Revenue Up 2%-4% >HBIO - Moomoo
Earnings call transcript: Harvard Bioscience Q1 2026 misses EPS forecast, stock drops By Investing.com - Investing.com South Africa
Harvard Bioscience Announces Q1 2026 Financial Results: $20.8M Revenue, 59% Gross Margin, Key SEC Filing Details 9 - Minichart
Harvard Bioscience Accelerates Growth with Human-Relevant Translational Tools, Leading Recurring Revenue and Innovation in Preclinical Research (May 2026) 10121415 - Minichart
Harvard Bioscience Still Sees 2026 Adjusted Ebitda Up 6%-10% >HBIO - Moomoo
Harvard Bioscience Inc (NASDAQ:HBIO) Q1 Results Show Revenue Miss Offsets Earnings Beat - ChartMill
HARVARD BIOSCIENCE ($HBIO) Releases Q1 2026 Earnings - Quiver Quantitative
Harvard Bioscience Announces First Quarter 2026 Financial Results - The Manila Times
Harvard Bioscience: Q1 Earnings Snapshot - marketscreener.com
Harvard Bioscience (NASDAQ: HBIO) details debt refinancing, FY26 outlook and $7M convertible loan - Stock Titan
Harvard Bioscience (NASDAQ: HBIO) Q1 2026 margin up as loss shrinks - Stock Titan
Inventory turnover of Harvard Bioscience, Inc. – LS:A423J5 - TradingView
MSN Money - MSN
Harvard Bioscience Inc expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Harvard Bioscience to Participate in Upcoming Investor Conferences - 富途牛牛
HBIO News | HARVARD BIOSCIENCE INC (NASDAQ:HBIO) - ChartMill
Harvard Bioscience Inc (HBIO) 財務データ
収益
当期純利益
現金流量
EPS
1.04%
0.04%
大文字化:
|
ボリューム (24 時間):